Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award
Jaguar Health (NASDAQ:JAGX) announced that Dr. Eduardo Zimmer, a key collaborator with their joint venture Magdalena Biosciences, has received the prestigious Blas Frangione Early Career Achievement Award for 2024. This award recognizes early career researchers in Alzheimer's and dementia research. Magdalena, approximately 40% owned by Jaguar, is focused on developing novel, natural prescription psychoactive medicines from plants for mental health indications.
Magdalena recently initiated preclinical studies in Brazil to evaluate two botanical drug candidates for treating depression, anxiety, ADHD, and other neuropsychiatric conditions in adults. These studies use FDG PET scans to assess differential neuronal activity, with analysis performed by Dr. Zimmer's consultancy. The research aims to determine optimal dosing and therapeutic indications for potential future FDA approval as botanical drugs.
Jaguar Health (NASDAQ:JAGX) ha annunciato che il Dr. Eduardo Zimmer, un collaboratore chiave della loro joint venture Magdalena Biosciences, ha ricevuto il prestigioso Blas Frangione Early Career Achievement Award per il 2024. Questo premio riconosce i ricercatori emergenti nel campo della ricerca su Alzheimer e demenza. Magdalena, di proprietà per circa il 40% di Jaguar, è focalizzata sullo sviluppo di medicinali psicoattivi naturali di origine vegetale per indicazioni di salute mentale.
Magdalena ha recentemente avviato studi preclinici in Brasile per valutare due potenziali farmaci botanici per il trattamento di depressione, ansia, ADHD e altre condizioni neuropsichiatriche negli adulti. Questi studi utilizzano scansioni FDG PET per valutare l'attività neuronale differenziale, con analisi condotte dalla consulenza del Dr. Zimmer. La ricerca mira a determinare il dosaggio ottimale e le indicazioni terapeutiche per una potenziale futura approvazione da parte della FDA come farmaci botanici.
Jaguar Health (NASDAQ:JAGX) anunció que el Dr. Eduardo Zimmer, un colaborador clave en su empresa conjunta Magdalena Biosciences, ha recibido el prestigioso Blas Frangione Early Career Achievement Award para 2024. Este premio reconoce a los investigadores en etapas tempranas de sus carreras en la investigación sobre Alzheimer y demencia. Magdalena, propiedad de aproximadamente el 40% por Jaguar, se centra en el desarrollo de medicamentos psicoactivos naturales de origen vegetal para indicaciones de salud mental.
Recientemente, Magdalena ha iniciado estudios preclínicos en Brasil para evaluar dos candidatos a fármacos botánicos para tratar la depresión, la ansiedad, el TDAH y otras condiciones neuropsiquiátricas en adultos. Estos estudios utilizan escáneres PET con FDG para evaluar la actividad neuronal diferencial, con análisis realizados por la consultoría del Dr. Zimmer. La investigación tiene como objetivo determinar la dosificación óptima y las indicaciones terapéuticas para una futura aprobación potencial por la FDA como fármacos botánicos.
재규어 헬스 (NASDAQ:JAGX)는 그들의 합작 투자 마그달레나 바이오사이언스의 주요 협력자인 에두아르도 짐머 박사가 2024년 블라스 프란기오네 조기 경력 성과상을 수상했다고 발표했습니다. 이 상은 알츠하이머와 치매 연구에서 초기 경력 연구자들을 인정합니다. 재규어가 약 40% 소유하고 있는 마그달레나는 정신 건강을 위한 식물에서 유래한 새로운 자연 처방 약물 개발에 주력하고 있습니다.
마그달레나는 최근 브라질에서의 전임상 연구를 시작하여 성인의 우울증, 불안, ADHD 및 기타 신경 정신과적 질환 치료를 위한 두 가지 식물 약물 후보를 평가하고 있습니다. 이 연구는 FDG PET 스캔을 사용하여 차별적인 신경 활동을 평가하며, 짐머 박사의 자문을 통해 분석이 수행됩니다. 이 연구는 식물 약물로서 FDA의 잠재적인 미래 승인을 위한 최적의 용량과 치료 지침을 결정하는 것을 목표로 하고 있습니다.
Jaguar Health (NASDAQ:JAGX) a annoncé que le Dr. Eduardo Zimmer, un collaborateur clé de leur coentreprise Magdalena Biosciences, a reçu le prestigieux Blas Frangione Early Career Achievement Award pour 2024. Cette récompense reconnaît les chercheurs en début de carrière dans la recherche sur la maladie d'Alzheimer et la démence. Magdalena, dont Jaguar possède environ 40%, se concentre sur le développement de médicaments psychoactifs naturels d'origine végétale pour des indications de santé mentale.
Magdalena a récemment lancé des études précliniques au Brésil pour évaluer deux candidats à des médicaments botaniques pour le traitement de la dépression, de l'anxiété, du TDAH et d'autres conditions neuropsychiatriques chez les adultes. Ces études utilisent des scans PET FDG pour évaluer l'activité neuronale différentielle, l'analyse étant réalisée par le cabinet de conseil du Dr. Zimmer. La recherche vise à déterminer le dosage optimal et les indications thérapeutiques pour une éventuelle future approbation par la FDA en tant que médicaments botaniques.
Jaguar Health (NASDAQ:JAGX) gab bekannt, dass Dr. Eduardo Zimmer, ein wichtiger Mitarbeiter ihres Joint Ventures Magdalena Biosciences, den renommierten Blas Frangione Early Career Achievement Award für 2024 erhalten hat. Diese Auszeichnung erkennt Frühkarriere-Forscher in der Alzheimer- und Demenzforschung an. Magdalena, die zu etwa 40 % im Besitz von Jaguar ist, konzentriert sich auf die Entwicklung neuartiger, natürlicher rezeptpflichtiger psychoaktiver Medikamente aus Pflanzen für psychische Gesundheitsindikationen.
Magdalena hat kürzlich präklinische Studien in Brasilien begonnen, um zwei pflanzliche Arzneikandidaten zur Behandlung von Depressionen, Angstzuständen, ADHS und anderen neuropsychiatrischen Erkrankungen bei Erwachsenen zu bewerten. Diese Studien verwenden FDG-PET-Scans, um die differenzielle neuronale Aktivität zu bewerten, wobei die Analyse von der Beratung von Dr. Zimmer durchgeführt wird. Die Forschung zielt darauf ab, die optimale Dosierung und therapeutische Indikationen für eine potenzielle zukünftige Zulassung durch die FDA als pflanzliche Arzneimittel zu bestimmen.
- Magdalena Biosciences' key collaborator received a prestigious award, potentially enhancing the venture's credibility
- Preclinical studies initiated for two botanical drug candidates, progressing towards potential FDA approval
- Research focuses on multiple mental health indications, potentially expanding market opportunities
- Jaguar Health only owns approximately 40% of Magdalena Biosciences, limiting potential returns
- Botanical drug candidates are still in early preclinical stages, with no guarantee of success or FDA approval
Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health, is focused on developing novel prescription psychoactive plant-based medicines for various mental health indications
SAN FRANCISCO, CA / ACCESSWIRE / August 20, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Eduardo Zimmer, Ph.D., a key collaborator with Magdalena Biosciences ("Magdalena"), the joint venture formed by Jaguar and Filament Health Corp. (OTCQB:FLHLF)(CBOE CA:FH)(FSE:7QS) to develop novel, natural prescription psychoactive medicines derived from plants for mental health indications, is the 2024 recipient of the prestigious Blas Frangione Early Career Achievement Award. This award recognizes early career researchers whose cutting-edge research in Alzheimer's and dementia has the potential to impact the field by propelling it in novel directions.
"We're thrilled to see Dr. Zimmer, a key Brazil-based collaborator of Magdalena, recognized with this important award," said Dr. Karen Brunke, Jaguar's EVP of Corporate and Business Development and Acting CEO of Magdalena. "As announced, Magdalena recently initiated preclinical studies in Brazil to evaluate two botanical drug candidates for their potential to treat depression, anxiety, attention-deficit/hyperactivity disorder (ADHD) and other possible neuropsychiatric conditions initially in adults. These preclinical studies consist of evaluating botanical drug candidates in mice, using fluorodeoxyglucose positron emission tomography (FDG PET) scans to look for differential neuronal activity, and analysis of the FDG PET scans is being performed by Dr. Zimmer's consultancy, Z.M. Health Consultoria. We hope to see differential synaptic activity and communication in specific brain regions (connectivity) of interest for a range of mental disorders with these botanical drug candidates. These studies will help determine what dose as well as the best first therapeutic indication for these botanical drug candidates for possible use in humans, aimed at potential future FDA approval as botanical drugs."
Dr. Zimmer's acceptance speech for the award can be viewed by clicking here.
Dr. Zimmer is an assistant professor at Universidade Federal do Rio Grande do Sul (UFRGS) in Porto Alegre, Brazil, an adjunct professor at McGill Centre for Studies in Aging, Canada, and an Associate Researcher at the Brain Institute (Brazil). His research focuses on understanding the cellular origins of Alzheimer's, with a particular interest in neuroimaging, brain energy metabolism, and astrocytes. Dr. Zimmer's major findings include demonstrating that the in vivo activation or deactivation of astrocytes in rodents can change the brain FDG-PET signal, an imaging exam used in clinics as a biomarker of neurodegeneration, prompting a reconceptualization of its biological interpretation. He has received multiple individual awards, including the Best Brazilian Ph.D. thesis (2016) and the AAIC Neuroscience Next ‘One-to-Watch' Award (2021).
The Blas Frangione Award was established by and named for Blas Frangione, M.D., Ph.D., who is Professor Emeritus of Pathology and Psychiatry and Research Professor in the Departments of Pathology and Neurology at NYU Langone Medical Center. The Blas Frangione Foundation supports research in neuroscience.
Magdalena, which is currently approximately 40-percent owned by Jaguar, is focused on advancing plant-based innovation for patients and on identifying the next generation of plant-based first-in-class agents for treatment of mental health conditions. Botanical drug candidates have a long history of use by traditional healers and may have the potential for a new class of plant-based psychoactive drugs which are safe for daily at-home dosing.
About Botanicals Drugs
Botanicals drugs are defined by the U.S. Food and Drug Administration (FDA) as "products from plant materials, algae, macroscopic fungi, and combinations thereof." Many botanical drugs have a long history of safe use in traditional medicines, which may be documented and reviewed in scientific literature. Existing scientific literature on safety may accelerate the safety review process for a botanical drug, reducing the scope and financial burden for extensive safety studies. The FDA has established guidance on botanical drug development and recognizes the complexity of botanical drugs. Additionally, botanicals drugs, by virtue of their complexity, have the added benefit of being difficult to genericize. Hence there are often multiple opportunities for creating ‘trade-secrets,' as well as novel patents around a botanical drug substance, its processing, its formulation, and so forth.
About Filament Health (OTCQB:FLHLF)(CBOE CA:FH)(FSE:7QS)
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.
Learn more at www.filament.health and on Twitter and LinkedIn.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program at makecancerlessshitty.com and on X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that the two botanical drug candidates being analyzed with FDG PET scans may have the potential to be approved as botanical drugs. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
SOURCE: Jaguar Health, Inc.
View the original press release on accesswire.com
FAQ
What award did Jaguar Health's (JAGX) collaborator receive?
What is Magdalena Biosciences focusing on for Jaguar Health (JAGX)?
What preclinical studies has Jaguar Health (JAGX) initiated through Magdalena Biosciences?
What is the goal of Jaguar Health's (JAGX) preclinical studies through Magdalena Biosciences?
